☰

John C. Burnett, Ph.D. - Publications

Affiliations: 
2002-2008 Chemical Engineering University of California, Berkeley, Berkeley, CA, United States 
 2008-2017 Molecular and Cellular Biology Beckman Research Institute of City of Hope, Monrovia, CA, United States 
 2017- Center for Gene Therapy Beckman Research Institute of City of Hope, Monrovia, CA, United States 
Area:
viral gene delivery, stem cells, HIV
Website:
https://cal.berkeley.edu/burnett
Tree Info Similar researchers PubMed Report error

40 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Guan M, Lim L, Holguin L, Han T, Vyas V, Urak R, Miller A, Browning DL, Echavarria L, Li S, Li S, Chang WC, Scott T, Yazaki P, Morris KV, ... ... Burnett JC, et al. Pre-clinical data supporting immunotherapy for HIV using CMV-HIV-specific CAR T cells with CMV vaccine. Molecular Therapy. Methods & Clinical Development. 25: 344-359. PMID 35573050 DOI: 10.1016/j.omtm.2022.04.007  0.401
2022 Li S, Holguin L, Burnett JC. CRISPR-Cas9-mediated gene disruption of HIV-1 co-receptors confers broad resistance to infection in human T cells and humanized mice. Molecular Therapy. Methods & Clinical Development. 24: 321-331. PMID 35229006 DOI: 10.1016/j.omtm.2022.01.012  0.394
2021 Chaturvedi S, Vasen G, Pablo M, Chen X, Beutler N, Kumar A, Tanner E, Illouz S, Rahgoshay D, Burnett J, Holguin L, Chen PY, Ndjamen B, Ott M, Rodick R, et al. Identification of a therapeutic interfering particle-A single-dose SARS-CoV-2 antiviral intervention with a high barrier to resistance. Cell. PMID 34838159 DOI: 10.1016/j.cell.2021.11.004  0.611
2021 Holguin L, Echavarria L, Burnett JC. Novel humanized-PBMC mouse model with delayed onset of GVHD for preclinical HIV research. Journal of Virology. JVI0139421. PMID 34818071 DOI: 10.1128/JVI.01394-21  0.351
2021 Shrivastava S, Ray RM, Holguin L, Echavarria L, Grepo N, Scott TA, Burnett J, Morris KV. Exosome-mediated stable epigenetic repression of HIV-1. Nature Communications. 12: 5541. PMID 34545097 DOI: 10.1038/s41467-021-25839-2  0.468
2021 Setten RL, Chomchan P, Epps EW, Burnett JC, Rossi JJ. CRED9: A differentially expressed elncRNA regulates expression of transcription factor CEBPA. Rna (New York, N.Y.). PMID 34039742 DOI: 10.1261/rna.078752.121  0.481
2018 Arizala JA, Takahashi M, Burnett JC, Ouellet DL, Rossi JJ. Nucleolar Localization of HIV-1 Rev is Required Yet Insufficient for Production of Infectious Viral Particles. Aids Research and Human Retroviruses. PMID 29804468 DOI: 10.1089/Aid.2017.0306  0.651
2018 Satheesan S, Li H, Burnett JC, Takahashi M, Li S, Wu SX, Synold TW, Rossi JJ, Zhou J. HIV replication and latency in a humanized NSG mouse model during suppressive oral combinational ART. Journal of Virology. PMID 29343582 DOI: 10.1128/Jvi.02118-17  0.63
2016 Takahashi M, Wu X, Ho M, Chomchan P, Rossi JJ, Burnett JC, Zhou J. High throughput sequencing analysis of RNA libraries reveals the influences of initial library and PCR methods on SELEX efficiency. Scientific Reports. 6: 33697. PMID 27652575 DOI: 10.1038/Srep33697  0.466
2016 Dao P, Hoinka J, Takahashi M, Zhou J, Ho M, Wang Y, Costa F, Rossi JJ, Backofen R, Burnett J, Przytycka TM. AptaTRACE Elucidates RNA Sequence-Structure Motifs from Selection Trends in HT-SELEX Experiments. Cell Systems. 3: 62-70. PMID 27467247 DOI: 10.1016/J.Cels.2016.07.003  0.466
2016 Jung U, Takahashi M, Rossi JJ, Burnett JC. LGIT In Vitro Latency Model in Primary and T Cell Lines to Test HIV-1 Reactivation Compounds. Methods in Molecular Biology (Clifton, N.J.). 1354: 255-64. PMID 26714717 DOI: 10.1007/978-1-4939-3046-3_17  0.639
2015 Akkina RK, Allam A, Balazs AB, Blankson J, Burnett JC, Casares S, Garcia JV, Hasenkrug K, Kashanchi F, Kitchen S, Klein F, Kumar P, Luster AD, Poluektova LY, Rao M, et al. Improvements and Limitations of Humanized Mouse Models for HIV Research: NIH/NIAID "Meet the Experts" 2015 Workshop Summary. Aids Research and Human Retroviruses. PMID 26670361 DOI: 10.1089/Aid.2015.0258  0.418
2015 Saayman SM, Lazar DC, Scott TA, Hart JR, Takahashi M, Burnett JC, Planelles V, Morris KV, Weinberg MS. Potent and targeted activation of latent HIV-1 using the CRISPR/dCas9 activator complex. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 26581162 DOI: 10.1038/Mt.2015.202  0.563
2015 Petz LD, Burnett JC, Li H, Li S, Tonai R, Bakalinskaya M, Shpall EJ, Armitage S, Kurtzberg J, Regan DM, Clark P, Querol S, Gutman JA, Spellman SR, Gragert L, et al. Progress toward curing HIV infection with hematopoietic cell transplantation. Stem Cells and Cloning : Advances and Applications. 8: 109-16. PMID 26251620 DOI: 10.2147/SCCAA.S56050  0.581
2015 Bobbin ML, Burnett JC, Rossi JJ. RNA interference approaches for treatment of HIV-1 infection. Genome Medicine. 7: 50. PMID 26019725 DOI: 10.1186/S13073-015-0174-Y  0.668
2015 Takahashi M, Burnett JC, Rossi JJ. Aptamer-siRNA chimeras for HIV. Advances in Experimental Medicine and Biology. 848: 211-34. PMID 25757623 DOI: 10.1007/978-1-4939-2432-5_11  0.651
2015 Zhou J, Satheesan S, Li H, Weinberg MS, Morris KV, Burnett JC, Rossi JJ. Cell-specific RNA aptamer against human CCR5 specifically targets HIV-1 susceptible cells and inhibits HIV-1 infectivity. Chemistry & Biology. 22: 379-90. PMID 25754473 DOI: 10.1016/J.Chembiol.2015.01.005  0.654
2015 Saayman SM, Lazar DC, Scott TA, Burnett J, Takahashi M, Weinberg MS, Morris KV. 693. Potent and Targeted Activation of Latent HIV-1 Using Multiplexed Guide RNAs and the CRISPR/dCas9 Activator Complex Molecular Therapy. 23: S276. DOI: 10.1016/S1525-0016(16)34302-7  0.601
2015 Jung U, Castanotto D, Jung M, Burnett J, Rossi JJ. 692. A Novel RNAi Trigger Design Retains Potent, Target Specific Activity Despite Emerging Mutations in the Target Site Molecular Therapy. 23. DOI: 10.1016/S1525-0016(16)34301-5  0.54
2015 Takahashi M, Zhou J, Burnett JC, Rossi JJ. 581. Exploring Potency of Small RNAs for HIV Latency Reactivation Molecular Therapy. 23. DOI: 10.1016/S1525-0016(16)34190-9  0.679
2015 Satheesan S, Li H, Takahashi M, Zhou J, Burnett J, Rossi JJ. 580. In Vivo Analyses of Aptamers and siRNA Therapeutics Against HIV-1 in Humanized Mouse Model Molecular Therapy. 23. DOI: 10.1016/S1525-0016(16)34189-2  0.66
2014 Zhang X, Li H, Burnett JC, Rossi JJ. The role of antisense long noncoding RNA in small RNA-triggered gene activation. Rna (New York, N.Y.). 20: 1916-28. PMID 25344398 DOI: 10.1261/Rna.043968.113  0.515
2014 Chadalavada D, Adamson TW, Burnett JC, Chen RW, Rossi JJ. Irradiated compared with nonirradiated NSG mice for the development of a human B-cell lymphoma model. Comparative Medicine. 64: 179-85. PMID 24956209  0.355
2014 Zhou J, Ding Y, Burnett JC, Rossi J. Retroviruses for Cancer Therapy Cancer Gene Therapy by Viral and Non-Viral Vectors. 21-38. DOI: 10.1002/9781118501665.ch2  0.335
2013 Ouellet DL, Vigneault-Edwards J, Létourneau K, Gobeil LA, Plante I, Burnett JC, Rossi JJ, Provost P. Regulation of host gene expression by HIV-1 TAR microRNAs. Retrovirology. 10: 86. PMID 23938024 DOI: 10.1186/1742-4690-10-86  0.608
2013 Zhou J, Shum KT, Burnett JC, Rossi JJ. Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges. Pharmaceuticals (Basel, Switzerland). 6: 85-107. PMID 23667320 DOI: 10.3390/Ph6010085  0.498
2013 Snead NM, Wu X, Li A, Cui Q, Sakurai K, Burnett JC, Rossi JJ. Molecular basis for improved gene silencing by Dicer substrate interfering RNA compared with other siRNA variants. Nucleic Acids Research. 41: 6209-21. PMID 23620279 DOI: 10.1093/Nar/Gkt200  0.524
2013 Zhou J, Tiemann K, Chomchan P, Alluin J, Swiderski P, Burnett J, Zhang X, Forman S, Chen R, Rossi J. Dual functional BAFF receptor aptamers inhibit ligand-induced proliferation and deliver siRNAs to NHL cells. Nucleic Acids Research. 41: 4266-83. PMID 23470998 DOI: 10.1093/Nar/Gkt125  0.487
2012 Zhou J, Bobbin ML, Burnett JC, Rossi JJ. Current progress of RNA aptamer-based therapeutics. Frontiers in Genetics. 3: 234. PMID 23130020 DOI: 10.3389/Fgene.2012.00234  0.521
2012 Burnett JC, Zaia JA, Rossi JJ. Creating genetic resistance to HIV. Current Opinion in Immunology. 24: 625-32. PMID 22985479 DOI: 10.1016/J.Coi.2012.08.013  0.656
2012 Burnett JC, Rossi JJ. RNA-based therapeutics: current progress and future prospects. Chemistry & Biology. 19: 60-71. PMID 22284355 DOI: 10.1016/J.Chembiol.2011.12.008  0.536
2012 Dey SS, Xue Y, Joachimiak MP, Friedland GD, Burnett JC, Zhou Q, Arkin AP, Schaffer DV. Mutual information analysis reveals coevolving residues in Tat that compensate for two distinct functions in HIV-1 gene expression. The Journal of Biological Chemistry. 287: 7945-55. PMID 22253435 DOI: 10.1074/Jbc.M111.302653  0.746
2011 Burnett JC, Rossi JJ, Tiemann K. Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnology Journal. 6: 1130-46. PMID 21744502 DOI: 10.1002/Biot.201100054  0.538
2010 Skupsky R, Burnett JC, Foley JE, Schaffer DV, Arkin AP. HIV promoter integration site primarily modulates transcriptional burst size rather than frequency. Plos Computational Biology. 6. PMID 20941390 DOI: 10.1371/Journal.Pcbi.1000952  0.749
2010 Burnett JC, Lim KI, Calafi A, Rossi JJ, Schaffer DV, Arkin AP. Combinatorial latency reactivation for HIV-1 subtypes and variants. Journal of Virology. 84: 5958-74. PMID 20357084 DOI: 10.1128/Jvi.00161-10  0.761
2009 Burnett JC, Rossi JJ. Autologous cell therapy for HIV: Stem cells, ribozymes and HIV Gene Therapy. 16: 1178-1179. PMID 19641534 DOI: 10.1038/Gt.2009.86  0.666
2009 Burnett JC, Miller-Jensen K, Shah PS, Arkin AP, Schaffer DV. Control of stochastic gene expression by host factors at the HIV promoter. Plos Pathogens. 5: e1000260. PMID 19132086 DOI: 10.1371/Journal.Ppat.1000260  0.75
2008 Leonard JN, Shah PS, Burnett JC, Schaffer DV. HIV evades RNA interference directed at TAR by an indirect compensatory mechanism. Cell Host & Microbe. 4: 484-94. PMID 18996348 DOI: 10.1016/J.Chom.2008.09.008  0.773
2005 Weinberger LS, Burnett JC, Toettcher JE, Arkin AP, Schaffer DV. Stochastic gene expression in a lentiviral positive-feedback loop: HIV-1 Tat fluctuations drive phenotypic diversity. Cell. 122: 169-82. PMID 16051143 DOI: 10.1016/J.Cell.2005.06.006  0.773
2005 Weinberger LS, Burnett JC, Toettcher JE, Arkin AP, Schaffer DV. Stochastic gene expression in a lentiviral positive feedback loop: HIV-1 tat fluctuations drive phenotypic diversity Aiche Annual Meeting, Conference Proceedings. 10416.  0.764
Show low-probability matches.